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Abstract
Introduction Neoadjuvant systemic therapy (NST) is an
established strategy to reduce tumor size in breast cancer
patients prior to breast-conserving therapy. The effect of NST on
tumor cell dissemination in these patients is not known. The aim
of this study was to investigate the incidence of disseminated
tumor cells (DTC), including apoptotic DTC, in breast cancer
patients after NST, and to investigate the correlation of DTC
status with therapy response.
Methods Bone marrow aspiration was performed in 157
patients after NST. DTC were detected by
immunocytochemistry using the A45–B/B3 anticytokeratin
antibody. To detect apoptotic DTC the antibody M30 (Roche
Diagnostics, Germany) was used, which detects a neo-epitope
expressed only after caspase cleavage of cytokeratin 18 during
early apoptosis.
Results The incidence of DTC in breast cancer patients was
53% after completion of NST. Tumor dissemination was
observed more frequently in patients with no change/
progressive disease (69%) than in patients with partial
remission or complete remission of the primary tumor (46%) (P
< 0.05). Ten out of 24 patients with complete remission,
however, were still bone marrow positive. Apoptotic DTC were
present in 36 of 157 (23%) breast cancer patients. Apoptotic
cells only were detected in 14% of the patients with partial
remission or complete remission, but were detected in just 5%
of the patients with stable disease. Apoptotic DTC were
detectable in none of the patients with tumor progression.
Conclusion The pathological therapy response in breast cancer
patients is reflected by the presence of apoptotic DTC. Patients
with complete remission, however, may still have nonapoptotic
DTC. These patients may also benefit from secondary adjuvant
therapy.
Introduction
Neoadjuvant systemic therapy (NST) has become the stand-
ard treatment for locally advanced breast cancer. The major
aim of systemic therapy in these patients is to facilitate breast-
conserving surgery. In recent years NST has also been offered
to patients with smaller tumors who were expected to receive
systemic therapy, since NST offers the possibility for in vivo
chemosensitivity testing [1-4]. Moreover, prognostic informa-
tion can be obtained based on the pathologic response to
chemotherapy. Patients with complete remission of the pri-
mary tumor have a better clinical outcome compared with
those with partial remission or compared with nonresponders
[5,6].
Local therapy response is normally assessed by palpation and
imaging techniques including ultrasound and mammography.
The efficacy of neoadjuvant treatment on disseminated tumor
cells (DTC) is assumed to be correlated to local therapy
response. Complete remission is considered a surrogate
marker for complete eradication of micrometastatic disease.
However, 13–25% of patients with pathological complete
response develop metastatic disease over 5 years [1,5-8].
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Eradication of a minimal residual disease may be monitored by
serial bone marrow analysis during NST, offering new insights
into the effects of systemic therapy on minimal residual dis-
ease. DTC can be detected in 30–40% of untreated primary
breast cancer patients prior to surgery [9-12]. Tumor cell per-
sistence after removal of the primary tumor and adjuvant chem-
otherapy has been suggested to indicate chemotherapy
resistance and poor clinical outcome [13-15]. The efficacy of
neoadjuvant chemotherapy may therefore be indicated by
bone marrow negativity or by the presence of disseminated
apoptotic cells that were susceptible to cytotoxic agents.
The main focus of this study was to investigate the incidence
of DTC, including apoptotic DTC, in patients with breast can-
cer after primary chemotherapy, and to investigate the correla-
tion of the DTC status with pathological therapy response.
Patients and methods
Patients
Primary breast cancer patients (cT1–T4, cN0–N2) who had
received systemic therapy and who had undergone surgery at
the Department of Gynecology and Obstetrics, University
Hospital, Tuebingen, Germany from January 2002 until Janu-
ary 2005 were included in the analysis. Exclusion criteria were
a previous history of cancer or a secondary malignancy. Both
patients treated with endocrine therapy and patients treated
with chemotherapy were included in current trials and
received standard treatment. Patients in the endocrine therapy
group received either letrozole (n = 9) or exemestane (n = 6).
Patients in the chemotherapy group were treated with either
taxane-based (n  = 110) or anthracycline-based (n  = 32)
chemotherapeutic regimens.
The clinical data of patients are summarized in Table 1. The
assessment of clinical response included ultrasound, mam-
mography and physical examination. Clinical complete remis-
sion was defined as a complete disappearance of the tumor
mass. Partial remission was defined as a reduction of the pri-
mary tumor size by 50% or more at the time of surgery. Stable
disease was defined as no significant increase or a decrease
in tumor size. Progressive disease was defined as the devel-
opment of new, previously undetected lesions or an increase
in the size of a preexisting lesion by 25% after at least two
treatment cycles.
Three weeks to 4 weeks after completion of the final cycle of
systemic therapy, surgery and bone marrow aspiration were
performed. Surgical breast and axillary node resection speci-
mens were evaluated for pathologic tumor response. Patients
who had no remaining invasive cancer in the breast and who
were lymph node negative were considered to have patholog-
ical complete response.
Bone marrow status and immunohistochemistry
Ten millilitres and 20 ml bone marrow were aspirated intraop-
eratively from the anterior iliac crest prior to surgery as a rou-
tine procedure and were processed within 24 hours. All
specimens were obtained after written informed consent from
the patient. Tumor cell isolation and detection were performed
based on the Consensus Recommendations for Standardized
Tumor Cell Detection [16]. Mononuclear cells were obtained
by density gradient centrifugation (density 1.077 g/ml, Ficoll;
Biochrom, Berlin, Germany) and cytospins were prepared
(106 mononuclear cells/spot) using a cytocentrifuge (Hettich,
Tuttlingen, Germany).
For detection of cytokeratin-positive tumor cells, slides were
fixed in 4% neutral buffered formalin for 10 minutes and were
rinsed in phosphate-buffered saline. Automatic immunostain-
ing was performed on the DAKO autostainer using the mono-
clonal mouse A45–B/B3 antibody (Micromet, München,
Germany) and the DAKO-APAAP detection kit (DakoCytoma-
tion, Glostrup, Denmark) according to the manufacturers'
instructions. The A45–B/B3 antibody is directed against com-
mon cytokeratin epitopes including the cytokeratin heterodim-
ers 8/18 and 8/19.
For each patient, 2 × 106 cells were analyzed (two slides).
Slides were automatically scanned using the ACIS™ imaging
system (ChromaVision, Medical Systems Inc., San Juan, Cap-
istrano, CA, USA). Criteria for evaluation of immunostained
cells were based on the criteria of the European ISHAGE
Working group for standardization of tumor cell detection
[17]. MCF-7 was used as a positive control. Leukocytes from
healthy volunteers served as the negative control.
Additional slides from each patient were stained using the
M30 antibody (Roche Applied Science, Mannheim, Germany)
and the APAAP kit detection method as described above. The
antibody reacts with a neo-epitope expressed only after cas-
pase cleavage of cytokeratin 18 during early apotosis [18,19].
Identification of apoptotic tumor cells were based on positive
M30 staining and cytomorphological criteria as described
elsewhere [20,25-27].
Statistical analysis
The chi-squared test was used to examine the relationship
between bone marrow micrometastases and clinicopathologi-
cal factors. Statistical analysis was performed by SPSS (ver-
sion 11.5; SPSS, Chigaco, Illinois, USA). P  < 0.05 was
considered statistically significant.
Results
Patients and primary tumor data
A total of 157 patients were included in the analysis. Table 1
summarizes the patients' characteristics. The median age of
patients was 53 years (range, 24–85 years). Most patients
had ypT2–ypT4 tumors after NST. Positive lymph nodes wereAvailable online http://breast-cancer-research.com/content/8/5/R60
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Table 1
Basic characteristics of patients with primary systemic therapy
Characteristic n Bone marrow positive P value
n %
Total 1 5 7 8 45 3-
Menopausal status 0.3
Premenopausal 72 42 58
Postmenopausal 85 42 49
Tumor size 0.6
ypT0 24 10 44
ypT1 61 33 54
ypT2–ypT4 73 41 56
Nodal status 0.5
ypN negative 75 38 51
ypN positive 82 46 56
Estrogen receptor status 1.0
Negative 39 21 54
Positive 118 63 53
Progesterone receptor status 0.7
Negative 68 35 52
Positive 89 49 55
HER2 status
Negative (score 0/+1 by immunohistochemistry) 115 63 54 0.7
Positive (score +2/+3 by immunohistochemistry) 39 20 51
Grading 0.9
I–II 109 58 53
III 41 21 51
Histology 0.2
Ductal 97 48 49
Lobular 33 17 52
Others 27 19 70
Primary systemic therapy 0.3
Chemotherapy 142 78 55
Hormonal therapy 15 6 40
Response to neoadjuvant systemic therapya <0.05c
Pathological complete remission 24 10 (4)b 42 (17)b
Partial remissiond 87 42 (11)b 48 (13)b
Stable disease 40 27 (2)b 68 (5)b
Progressive disease 5 4 (0)b 80 (0)b
aNot including apoptotic cells (see Table 2). bNumber (percentage) of patients with only apoptotic cells. cComplete remission + partial remission 
(46%) versus stable disease + progressive disease (69%). dPartial remission also includes patients with clinical complete remission but 
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seen in 52% of patients. The predominant tumor type was the
invasive ductal carcinoma (97 of 157 cases). Sixty-two per
cent of patients were positive for estrogen receptor and 49%
were positive for progesterone receptor. The HER2 status
was positive in 25% of patients.
Response to primary systemic therapy
Response rates to therapy are presented in Table 1. Of the
157 patients, 142 received chemotherapy. The remaining
patients were treated with endocrine therapy. Twenty-four out
of 157 patients showed pathological complete remission. Par-
tial remission was seen in 84 patients. Stable disease or pro-
gression was observed in 42 patients and five patients,
respectively.
Correlation with prognostic factors
The incidence of DTC in breast cancer patients was 53% (84
out of 157 patients) after completion of NST (apoptotic DTC
were not taken into account for this analysis) (Figure 1a). No
correlation could be observed with any of the established
prognostic factors, including the lymph node status, the tumor
size, the hormone receptor status or the grading. Tumor dis-
semination was observed more frequently in patients with no
change/progressive disease (69%) than in those patients who
showed partial remission or complete remission of the primary
tumor (46%) (P < 0.05). Ten out of 24 (42%) patients with
complete remission, however, were still bone marrow positive.
Presence of apoptotic cells
Bone marrow was analyzed for the presence of apoptotic cells
by M30 staining. Apoptotic tumor cells could be detected in
36 out of 157 (23%) breast cancer patients (Figure 1b). Sev-
enteen patients had only apoptotic cells in their bone marrow,
whereas 19 patients had both apoptotic cells and nonapop-
totic cells. The presence of only apoptotic cells was higher in
bone-marrow-positive patients with partial remission or com-
plete remission (14%) compared with those patients with sta-
ble disease or progressive disease (4%) (P  < 0.05). No
apoptotic tumor cells were detected in patients with tumor
progression (n = 5). Interestingly, 10 of the 24 patients with
complete remission also had nonapoptotic cells. Data are
summarized in Table 2.
Discussion
Over the past years, neoadjuvant chemotherapy has become
increasingly important even in smaller tumors and may to date
already be considered a standard strategy in locally advanced
disease. Neoadjuvant chemotherapy not only increases the
rate of breast-conserving surgery, but also allows an in vivo
chemosensitivity testing [1]. The response to NST is closely
correlated to disease-free survival and overall survival [5,6].
Nevertheless approximately 15–25% of the complete remis-
sion patients will develop metastatic disease within 5 years
after surgery, suggesting subclinical tumor cell persistence
after systemic therapy [5-8]. Since DTC reflect the first step of
a subclinical tumor cell spread [20], the aim of the present
study was to investigate the bone marrow status in patients
after completion of neoadjuvant therapy. Moreover, to further
investigate the effect of chemotherapy on residual tumor cells,
M30 staining as a marker for apoptosis was applied to DTC
and correlated to the clinical and pathological response to
therapy of the primary tumor.
Response of the primary tumor is reflected by bone 
marrow status
DTC were detected in 53% of patients after completion of
neoadjuvant therapy. The highest positivity rate was observed
in patients with progressive disease (80%), followed by
patients with stable disease (68%) and those with partial
remission (48%). Only 10 of 24 (42%) patients with patholog-
ical complete remission were DTC positive. The response of
the primary tumor was therefore reflected by the presence of
DTC. Interestingly, the overall incidence was higher compared
with the preoperative positivity rates reported in primary breast
cancer patients prior to surgery and not treated by chemother-
apy, ranging from 30% to 50% [9-12]. Most of the patients,
however, had initially advanced stages with nodal involvement.
In general, these patients tend to have higher positivity rates in
the bone marrow. In addition, most of the patients still have
Figure 1
Disseminated apoptotic and nonapoptotic disseminated tumor cells Disseminated apoptotic and nonapoptotic disseminated tumor cells. 
(a) Nonapoptotic disseminated tumor cell (DTC) (detected by the 
APAAP kit method). (b) Apoptotic DTC identified by M30 staining and 
morphological assessment (for example, membrane blebbing, nuclear 
shrinkage) (APAAP kit detection method). (c) Apoptotic DTC identified 
by morphological assessment (nuclear shrinkage, cytokeratin inclu-
sions) (DTC detected by a fluorescein-5-isothiocyanate-labeled anticy-
tokeratin antibody). (d) Apoptotic cell body without detectable amounts 
of chromatin.Available online http://breast-cancer-research.com/content/8/5/R60
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tumor left despite neoadjuvant chemotherapy. It has been
shown that regressing tumors still shed tumor cells into the
blood circulation to the same extent as progressing tumors
[21]. Therefore, even if patients respond to chemotherapy,
cells may be still shed into the bone marrow until removal of
the primary tumor. Most of these cells may have no relevance
and undergo apoptosis induced by cytotoxic agents.
Presence of apoptotic cells in bone marrow after 
systemic treatment
Apoptosis is programmed cell death, which represents a sign-
aling pathway that leads to cellular suicide in an organized
manner. Apoptosis is fundamentally different from the necrotic
mode of cell death, in which the cells suffer a major insult,
resulting in a loss of membrane integrity, swelling and disrup-
ture of the cell. The gold standard for detection of apoptosis
has been morphological assessment either with electronic
microscopy or with light microscopy [22-28]. Cells are charac-
terized by specific morphologic signs of celllular shrinkage,
membrane blebbing (cleavage of cytoskeletal proteins leading
to blebbing), nuclear condensation and fragmentation [26].
The alteration of the cytoskeleton takes place first [42] and the
intact intermediate filament network is then replaced by cytok-
eratin inclusions (Figure 1c). The final stages are apoptotic
bodies (Figure 1c,d) [28].
Given that apoptosis is the principle mechanism of chemother-
apy-induced regression [29], we analyzed the bone marrow
aspirates for the presence of apoptotic DTC by immunocyto-
chemical staining with M30 antibody. This antibody reacts
with a caspase cleaved epitope of cytokeratin 18 expressed
during early apoptosis [18].
No apoptotic DTC could be detected in the bone marrow of
patients with progressive disease, whereas the positivity rate
of only apoptotic DTC was 4% in patients with stable disease
versus 14% in patients with partial remission or complete
remission. The presence of only apoptotic DTC was therefore
reflected by the therapy response. A subset of patients with
stable disease, partial remission or complete remission had
both apoptotic cells and nonapoptotic cells, reflecting hetero-
geneity in terms of therapy responsiveness also observed in
the primary tumor [30].
Clinical relevance of disseminated tumor cells in 
patients with complete remission
The most interesting group of patients to elucidate the biology
of chemoresistance and metastatic disease are those with
complete remission of the primary tumor and persisting tumor
cells in the bone marrow. The aim of (neo)adjuvant chemother-
apy is to eradicate micrometastatic disease to improve dis-
ease-free survival and overall survival. Theoretically, if
complete remission indicates complete eradication of meta-
static disease, no patients with complete remission should
have disseminated DTC or should develop metastatic disease
during the course of disease. Several studies have shown, in
fact, that patients without DTC have the best outcome. How-
ever, 13–25% of these patients suffer from systemic relapse.
Since no primary tumor is left, one of the sources of metastatic
cells is likely to be in the bone marrow. In our study, nonapop-
totic DTC could be detected in 10 out of 24 (42%) patients
with complete remission. Similar positive rates of tumor cell
persistence have also been observed in breast cancer patients
after surgery and completion of adjuvant therapy [13-15].
These DTC have the capability to survive in the blood circula-
tion despite cell-matrix loss and are apparently resistant to sys-
temic therapy. Two important steps of the metastatic cascade
are therefore fulfilled [21]. Since it has already been demon-
strated that patients with persistent DTC have a poor progno-
sis [13-15], determination of the bone marrow status after
neoadjuvant chemotherapy might identify those patients at a
high risk for metastatic disease and identify patients who may
need secondary therapy.
Clearly not all disseminated cells may necessarily be cells with
metastatic potential, however, since the positivity rate of 42%
is higher than the expected relapse rate for patients with com-
plete remission, ranging from 13 to 25%. Meng and col-
leagues [31] have shown that circulating tumor cells can be
detected in the blood of breast cancer patients more than 20
Table 2
Bone marrow findings subdivided after response to primary therapy
Bone marrow findings Poor responder (n = 45) Responder (n = 111)
Progressive 
disease 
(n = 5)
Stable 
disease 
(n = 40)
Stable disease + 
progressive disease 
(n = 45)
Partial remission
 (n = 87)
Complete 
remission 
(n = 24)
Partial remission + 
complete remission 
(n = 111)
Disseminated tumor cell negative (n = 56) 1 (20%) 11 (28%) 12 (26%) 34 (39%) 10 (42%) 44 (40%)
Only apoptotic cells (n = 17) 0 (0%) 2 (5%) 2 (4%) 11 (13%) 4 (17%) 15 (14%)
Nonapoptotic cells + apoptotic cells (n = 19) 0 (0%) 7 (18%) 7 (16%) 10 (12%) 2 (8%) 12 (11%)
Nonapoptotic cells (n = 64) 4 (80%) 20 (50%) 24 (52%) 32 (37%) 8 (33%) 40 (36%)Breast Cancer Research    Vol 8 No 5    Fehm et al.
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years after primary diagnosis without evidence for recurrence,
supporting the theory of (lifelong) tumor cell dormancy. An
important task will therefore be the identification of those per-
sistent and temporarily dormant cells that will cause a meta-
static disease. As a very provocative theory it has been
suggested that this subpopulation of persistent DTC may also
be seen as cancer stem cells since they are dormant but have
the ability to regrow following treatment [32,33]. Identification
and further characterization of this subset will offer the chance
to understand the mechanism of tumor cell growth and meta-
static disease. Furthermore, development of new drugs based
on these results will optimize treatment strategies since these
disseminated cells are directly linked to metastatic spread.
Conclusion
The presence of apoptotic tumor cells in bone marrow is
reflected by therapy response of the primary tumor to systemic
therapy. Patients with complete response, however, still may
have nonapoptotic DTC, indicating that the response of the
primary tumor does not necessarily reflect the therapeutic
effect on DTC. Even patients with complete remission but pos-
itive bone marrow status after primary systemic therapy may
therefore need secondary adjuvant therapy, which may be
based on bisphosphonates or antibody-based strategies, to
completely eradicate minimal residual disease.
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